Abstract
The pharmacological management of insomnia has lately become a challenge for researchers worldwide. As per the third International Classification of Sleep disorders (ICSD-3) insomnia can be defined as a state with repeated difficulty in sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunity and circumstances for sleep, and results in some form of daytime impairment. The conventional treatments approved for management of insomnia were benzodiazepines (BZDs) (estazolam, quazepam, triazolam, flurazepam and temazepam) and non-BZDs, also known as z-drugs (zaleplon, zolpidem, and eszopiclone), tricyclic antidepressant (TCA) doxepin as well as melatonin agonists, e.g. ramelteon. But the potential of these agents to address sleep problems has been limited due to substantial side effects associated with them like hangover, dependence and tolerance, rebound insomnia, muscular atonia, inhibition of respiratory system, cognitive dysfunctions, and increased anxiety. Recently, orexin neuropeptides have been identified as regulators of transition between wakefulness and sleep and documented to aid an initial transitory effect towards wakefulness by activating cholinergic/monoaminergic neural pathways of the ascending arousal system. This has led to the development of orexin peptides and receptors, as possible therapeutic targets for the treatment of sleep disorders with the advantage of having lesser side effects as compared to conventional treatments. The present review focuses on the orexin peptides and receptors signifying their physiological profile as well as the development of orexin receptor antagonists as novel strategies in sleep medicine.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- DR:
-
dorsal raphe
- DMH:
-
dorsomedial hypothalamus
- GPCR:
-
G protein coupled receptor
- GABA:
-
gamma amino butyric acid
- LDT:
-
laterodorsal tegmental nucleus
- LC:
-
locus coeruleus
- LPC:
-
lysophosphatydylcholine
- NMDA:
-
N-methyl-d-aspartate
- NSCC:
-
non-selective cationic channels
- OX1 R:
-
Orexin receptor 1
- OX2 R:
-
orexin receptor 2
- PPT:
-
pedunculopontine nucleus
- PUFAs:
-
polyunsaturated fatty acids
- VTA:
-
ventral tegmental area
- RAS:
-
reticular activating system
- VLPO:
-
venterolateral preoptic
- 5-HT:
-
5-hydroxy tryptamine
References
Roth T. Diagnosis and management of insomnia. Clin Cornerstone 2005;2: 28–38.
Fuller PM, Gooley JJ, Saper CB. Neurobiology of the sleep-wake cycle: sleep architecture, circadian, regulation, and regulatory feedback. J Biol Rhythms 2006;21:482–93.
Schwartz JR, Roth T. Neurophysiology of sleep and wakefulness basic science and clinical implications. Curr Neuropharmacol 2008;6:367–78.
España RA, Baldo BA, Kelley AE, Berridge CW. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience 2011;106:699–715.
Kilduff TS, Peyron C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci 2000;23:359–65.
Sakurai T, Mieda M. Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci 2011;32:451–62.
de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95:322–7.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573–85.
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469–74.
Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 2013;2:83–90.
Liu RJ, van den Pol AN, Aghajanian GK. Hypocretins(orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci 2002;22:9453–64.
van den Pol AN, Gao XB, Obrietan K, Kilduff TS, Belousov AB. Presynaptic and postsynapticactions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci 1998;18:7962–71.
Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 2006;49:589–601.
Borgland SL, Storm E, Bonci A. Orexin B/hypocretin 2 increases glutamatergic transmission toventral tegmental area neurons. Eur J Neurosci 2002;28: 1545–56.
Lu XY, Bagnol D, Burke S, Akil H, Watson SJ. Differential distribution and regulation of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon fasting. Horm Behav 2000;37:335–44.
Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001;435:6–25.
Gvilia I, Xu F, McGinty D, Szymusiak R. Homeostatic regulation of sleep: a role for preoptic area neurons. J Neurosci 2006;26:9426–33.
Sherin JE, Elmquist JK, Torrealba F, Saper CB. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J Neurosci 1998;18:4705–21.
Lu J, Bjorkum AA, Xu M, Gaus SE, Shiromani PJ, Saper CB. Selective activation of the extended ventrolateral preoptic nucleus during rapid eye movement sleep. J Neurosci 2002;22:4568–76.
Gallopin T, Fort P, Eggermann E, Cauli B, Luppi PH, Rossier J, et al. Identification of sleep-promoting neurons in vitro. Nature 2000;404:992–5.
Sakurai T, Mieda M, Tsujino N. The orexin system: roles in sleep/wake regulation. Ann N Y Acad Sci 2010;1200:149–61.
Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003;38:701–13.
Xie X, Crowder TL, Yamanaka A, Morairty SR, Lewinter RD, Sakurai T, et al. GABA(B) receptor-mediated modulation of hypocretin/orexin neurones in mouse hypothalamus. J Physiol 2006;574:399–414.
Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005;25:6716–20.
Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 1999;96:10911–16.
Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, et al. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res 2000;873:181–7.
Brown RE, Sergeeva OA, Eriksson KS, Haas HL. Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). J Neurosci 2002;22:8850–9.
Yamanaka A, Tsujino N, Funahashi H, Honda K, Guan JL, Wang QP, et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 2002;290:1237–45.
Eggermann E, Serafin M, Bayer L, Machard D, Saint-Mleux B, Jones BE, et al. Orexins/hypocretins excite basal forebrain cholinergic neurones. Neuroscience 2001;108:177–81.
Alam MN, Szymusiak R, Gong H, King J, McGinty D. Adenosinergic modulation of rat basal forebrain neurons during sleep and waking: neuronal recording with microdialysis. J Physiol 1999;521:679–90.
Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005;25:6716–20.
Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005;46:787–98.
Yamanaka A, Muraki Y, Ichiki K, Tsujino N, Kilduff TS, Goto K, et al. Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner. J Neurophysiol 2006;96:284–98.
Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001;14:1075–81.
Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000;12:726–30.
Kohlmeier KA, Watanabe S, Tyler CJ, Burlet S, Leonard CS. Dual orexin actions on dorsal raphe and laterodorsal tegmentum neurons: noisy cation current activation and selective enhancement of Ca2+ transients mediated by L-type calcium channels. J Neurophysiol 2008;100:2265–81.
Bayer L, Serafin M, Eggermann E, Saint-Mleux B, Machard D, Jones BE, et al. Exclusive postsynaptic action of hypocretin-orexin on sub layer 6b cortical neurons. J Neurosci 2004;24:6760–4.
Eriksson KS, Sergeeva O, Brown RE, Haas HL. Orexin/hypocretin excites the histaminergicneurons of the tuberomammillary nucleus. J Neurosci 2001; 21:9273–9.
Carter ME, Brill J, Bonnavion P, Huguenard JR, Huerta R, deLecea L. Mechanism for hypocretin-mediated sleep-to-wake transitions. Proc Natl Acad Sci USA 2012;109:E2635–44.
Tsunematsu T, Kilduff TS, Boyden ES, Takahashi S, Tominaga M, Yamanaka A. Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. J Neurosci 2011;31:10529–39.
Sasaki K, Suzuki M, Mieda M, Tsujino N, Roth B, Sakurai T. Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. PLoS ONE 2011;6:e20360.
Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T, Scammell TE. Behavioral state instability in orexin knock-out mice. J Neurosci 2004;24: 6291–300.
DinizBehn CG, Klerman EB, Mochizuki T, Lin SC, Scammell TE. Abnormal sleep/wake dynamics in orexin knockout mice. Sleep 2010;33:297–306.
Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2005;6:991–7.
Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553–62.
Prober DA, Rihel J, Onah AA, Sung RJ, Schier AF. Hypocretin/orexin over expression induces an insomnia-like phenotype in zebrafish. J Neurosci 2006;26:13400–10.
Yokogawa T, Marin W, Faraco J, Pézeron G, Appelbaum L, Zhang J, et al. Characterization of sleep in zebrafish and insomnia in hypocretin receptor mutants. PLoS Biol 2007;5:e277.
Willie JT, Takahira H, Shibahara M, Hara J, Nomiyama M, Yanagisawa M, et al. Ectopic overexpression of orexin alters sleep/wakefulness states and muscle tone regulation during REM sleep in mice. J Mol Neurosci 2011;43:155–61.
Dong HL, Fukuda S, Murata E. Orexins increase cortical acetylcholine release and electroencephalographic activation through orexin-1 receptor in the rat basal forebrain during isoflurane anesthesia. Anesthesiology 2006;104: 1023–32.
Hong ZY, Huang ZL, Qu WM. Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice. Acta Pharmacol Sin 2005;26:155–9.
Ishizuka T, Yamamoto Y, Yamatodani A. The effect of orexin-A and -B on the histamine release in the anterior hypothalamus in rats. Neurosci Lett 2002;323:93–6.
Vittoz NM, Berridge CW. Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: involvement of the ventral tegmental area. Neuropsychopharmacol 2006;31:384–95.
Tao R, Ma Z, McKhenna JT, Thakkar MM, Winston S, Strecker RE, et al. Differential effect of orexins (hypocretins) on serotonin release in the dorsal and median raphé nuclei of freely behaving rats. Neuroscience 2006;141:1101–5.
Bernard R, Lydic R, Baghdoyan HA. Hypocretin (orexin) receptor subtypes differentially enhance acetylcholine release and activate G protein subtypes in rat pontine reticular formation. J Pharmacol Exp Ther 2006;317:163–71.
Brevig HN, Watson CJ, Lydic R, Baghdoyan HA. Hypocretin GABA interacting the pontine reticular formation increase wakefulness. Sleep 2010;33: 1285–93.
Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam AH, Ming-Fung Wu MF, John J, et al. Release of hypocretin (orexin) during waking and sleep states. J Neurosci 2002;22:5282–6.
Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, et al. Promotion of sleep by targeting the orexin system in rats, dogs, and humans. Nat Med 2007;13:150–5.
Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97–111.
Hoever P, Haas SD, Winkler J, Schoemaker RC, Chiossi E, Gerven JV, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 2010;87:593–600.
Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D, Antolini M, et al. Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS ONE 2011;6:e16406.
Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology LXXXVI Orexin receptor function, nomenclature and pharmacology. Pharmacol Rev 2012;64:389–420.
Haynes AC, Jackson B, Chapman H, Tadayyon M, Johns A, Porter RA, et al. A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul Pept 2000;96:45–51.
Porter RA, Chan WN, Coulton S, Johns A, Hadley MS, Widdowson K, et al. 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg Med Chem Lett 2001;11:1907–10.
Winrow CJ, Gotter AL, Coleman PJ, Hargreaves R, Renger J. Recent chronology of orexin pharmacology and its potential as a treatment for primary insomni. In: Rankovic Z, Bingham M, Nestler EJ, Hargreaves R, editors. Drug discovery for psychiatric disorders. London: The Royal Society of Chemistry; 2012. p. 416–42.
McElhinny Jr. CJ, Lewin AH, Mascarella SW, Runyon S, Brieaddy L, Carroll FI. Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: possible confounding effects on in vivo and in vitro studies. Bioorg Med Chem Lett 2012;22:6661–4.
White CL, Ishii Y, Mendoza T, Upton N, Stasi LP, Bray GA, et al. Effect of a selective OX1R antagonist on food intake and body weight in two strains of rats that differ in susceptibility to dietary-induced obesity. Peptides 2005;26:2331–8.
Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S, et al. A key role for orexin in panic anxiety. Nat Med 2010;16:111–5.
Smith RJ, Aston-Jones G. Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur J Neurosci 2012;35:798–804.
Morairty SR, Revel FG, Malherbe P, Moreau JL, Valladao D, Wettstein JG, et al. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS ONE 2012;7:e39131.
Steiner MA, Gatfield J, Roch BC, Dietrich H, Treiber A, Jenck F, et al. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. Chem Med Chem 2013;8:898–903.
Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, et al. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol 2009;156: 1326–41.
Kummangal BA, Kumar D, Mallick HN. Intracerebro ventricular injection of orexin-2 receptor antagonist promotes REM sleep. Behav Brain Res 2013; 237:59–62.
Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes M, et al. LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Front Neurosci 2014;2014(8):5.
Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, et al. Discovery of 5-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2′:5′,3-terpyridine-3′-carbo xamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Chem Med Chem 2014;9:311–22.
Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, et al. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014;24:4884–90.
https://clinicaltrials.gov/ct2/show/NCT01995838 [accessed 28.08.15].
http://ir.minervaneurosciences.com/JNJ-42847922 [accessed 28.08.15].
Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang XH, Sutton SW. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009;330:142–51.
Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA. SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol 2001;132: 1179–82.
Rodgers RJ, Halford JC, Nunes de Souza RL, Canto de Souza AL, Piper DC, Arch JR, et al. SB-334867, selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur J Neurosci 2001;13:1444–52.
Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ. Characterisation of the binding of [3H]-SB-6740421, a novel non peptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 2004;141:340–6.
Steiner MA, Sciarretta C, Pasquali A, Jenck F. The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front Pharmacol 2013;4:165.
Hirose M, Egashira S, Goto Y, Hashihayata T, Ohtake N, Iwaasa H, et al. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroiso-quinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett 2003;13:4497–9.
Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, et al. Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J Pharmacol Exp Ther 2015. http://dx.doi.org/10.1124/jpet.115.225466.
Neubauer DN. Almorexant a dual orexin receptor antagonist for the treatment of insomnia. Curr Opin Investig Drugs 2010;11:101–10.
Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol 2009;76:618–31.
Pałasz A, Lapray D, Peyron C, Gołębiewska ER, Skowronek R, Markowski G, et al. Dual orexin receptor antagonists — promising agents in the treatment of sleep disorders. Int J of Neuropsychopharmacol 2014;17:157–68.
https://clinicaltrials.gov/ct2/show/NCT01243060 [accessed 15.03.15].
Mang GM, Durst T, Burki H, Imobersteg S, Abramowski D, Schuepbach E, et al. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 2012;35: 1625–35.
Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J. Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol 2012;26:1071–80.
Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, et al. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 2011;25:52–61.
Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methy 1-2-(2H-1,2,3-triazol-2-yl) phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010;53:5320–32.
Bennett T, Bray D, Neville MW. Suvorexant, a dual orexin receptor antagonist for the management of insomnia. PT 2014;39(4):264–6.
Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 2012;79:2265–74.
Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013;36:259–67.
Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, et al. Pharmacological characterization of MK-6096: A dual orexin receptor antagonist for insomnia. Neuropharmacology 2012;62:978–87.
Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, et al. Pharmacological characterization of MK-6096 — a dual orexin receptor antagonist for insomnia. Neuropharmacology 2012;62:978–87.
Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ, et al. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl) phenyl] methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. Chem Med Chem 2012;7:415–24.
https://www.clinicaltrialsregister.eu/ctr-search [accessed 15.03.15].
Di Fabio R, Pellacani A, Faedo S, Roth A, Piccoli L, Gerrard P. Discovery process and pharmacological characterization of a novel dual orexin1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bio org Med Chem Lett 2011;21:5562–7.
Bettica P, Squassante L, Zamuner S, Nucci G, Danker HH, Ratti E. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 2012;35:1097–104.
Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 2012;35:1097–104.
https://clinicaltrials.gov/ct2/show/NCT00426816 [accessed 15.03.15].
http://www.gsk-clinicalstudyregister.com/compounds/sb649868 [accessed 20.03.15].
http://fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.html [accessed 17.03.15].
https://federalregister.gov/articles/2014/02/13/2014-03124/schedules-of-controlled-substances-placement-of-suvorexant-into-schedule-iv [accessed 28.03.15].
http://belsomra.com/ [accessed 17.03.15].
http://en.apdnews.com/news/7ff7b8a890574d1cbb50675732d6873a.html [accessed 18.03.15].
Yoshida Y, Taro T, Yoshimitsu N, Yuji K, Fumihiro O, Carsten T, et al. Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists. Bioorg Med Chem 2014;22:6071–88.
http://www.eisai.com/news/news201477 [accessed 28.08.15].
Boss C. Orexin receptor antagonists-a patent review (2010 to August 2014). Expert Opin Ther Pat 2014;24:1367–81.
Hoch M, Helene van G, Joop van G, Jasper D. Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant. J Clin Pharma 2014;54:979–86.
Risberg A, Risberg J, Ingvar D. Effects of promethazine on nocturnal sleep in normal man. Psychopharmacologia 1975;43:279–84.
Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010;24:1577–601.
Lanoir J, Killam EK. Alteration in the sleep-wakefulness patterns by benzodiazepines in the cat. Electroencephalogr Clin Neurophysiol 1968;25: 530–42.
Borbély AA, Mattmann P, Loepfe M, Strauch I, Lehmann D. Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol 1985;4: 189–94.
Gaillard JM, Schulz P, Tissot R. Effects of three Benzodiazepines (Nitrazepam, Flunitrazepam and Bromazepam) on sleep of normal subjects, studied with an automatic sleep scoring system. Pharmacopsychiatry 2009;6:207–17.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kumar, A., Chanana, P. & Choudhary, S. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs. Pharmacol. Rep 68, 231–242 (2016). https://doi.org/10.1016/j.pharep.2015.09.002
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2015.09.002